Actavia Life Sciences, Inc.
RASP · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.10 | 0.00 | 0.46 |
| FCF Yield | -0.59% | -0.80% | 0.06% | 0.05% |
| EV / EBITDA | -89.13 | -49.46 | -1,231.06 | 0.00 |
| Quality | ||||
| ROIC | 3.80% | 6.66% | 2.80% | 5.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.37 | 0.32 | -0.11 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 24.32% | -808.32% | -33.14% | 142.02% |
| Safety | ||||
| Net Debt / EBITDA | -4.27 | -1.66 | -14.31 | 0.00 |
| Interest Coverage | -2.90 | -5.36 | -5.08 | -20.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |